1. Home
  2. ZTEK vs VANI Comparison

ZTEK vs VANI Comparison

Compare ZTEK & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zentek Ltd.

ZTEK

Zentek Ltd.

HOLD

Current Price

$0.71

Market Cap

89.3M

Sector

Industrials

ML Signal

HOLD

Logo Vivani Medical Inc. (DE)

VANI

Vivani Medical Inc. (DE)

HOLD

Current Price

$1.38

Market Cap

81.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZTEK
VANI
Founded
2008
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.3M
81.2M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
ZTEK
VANI
Price
$0.71
$1.38
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
41.1K
167.5K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$657,134.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2225.73
N/A
52 Week Low
$0.62
$0.91
52 Week High
$1.84
$1.92

Technical Indicators

Market Signals
Indicator
ZTEK
VANI
Relative Strength Index (RSI) 40.93 45.19
Support Level $0.70 $1.25
Resistance Level $0.75 $1.55
Average True Range (ATR) 0.05 0.07
MACD -0.00 0.01
Stochastic Oscillator 12.50 40.00

Price Performance

Historical Comparison
ZTEK
VANI

About ZTEK Zentek Ltd.

Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.

About VANI Vivani Medical Inc. (DE)

Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.

Share on Social Networks: